Device Trial Radar · NCT07422259
Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 9, 2025
Primary completion
Sep 3, 2025
Study completion Sep 3, 2025
Sponsor
- Lead sponsor
- Medivis SRLNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- University of Messina
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical investigation #1122 is a Post Market Clinical Follow Up Study on the EC marked medical device Reinnerva/Lubristil +G, sterile eye drops, compared to Vismed medical device, sterile eye drops, to demonstrate the clinical performance and tolerability of Reinnerva/Lubristil +G to stabilize the lacrimal film and improve the ocular surface condition in the cases of quali-quantitative alterations of the tear film .
Conditions
- Keratoconjunctivitis Sicca
Interventions
Reinnerva/Lubristil +G sterile eye drops (artificial tears)Device
2 drops instilled in 1 eye, 2 times daily, for 60 days
Vismed sterile eye drops (artificial tears)Device
2 drops instilled in 1 eye, 4 times daily, for 60 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Performance and BenefitTime frame: From enrollment to the end of treatment at 30 and 60 days.
5 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UOC of Ophthalmology, AOU Policlinico "G. Martino"
Messina, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.